We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel X-Linked Intellectual Disability Genes Identified

By LabMedica International staff writers
Posted on 24 Feb 2015
A novel group of genes on the X-chromosome that when mutated lead to the mental disorder X-linked intellectual disability (XLID) have been added to list of more than a 100 such genes that had been identified previously.

XLID is a generalized neurodevelopmental disorder characterized by significantly impaired intellectual and adaptive functioning. More...
It is defined by an IQ score below 70 in addition to deficits in two or more adaptive behaviors that affect everyday general living. The syndrome is caused by mutations on the X-chromosome. Since males have only one X-chromosome and the syndrome is passed on in a recessive manner, the disorder mainly occurs in boys. Over the past 20 years more than 100 X-chromosome genes linked to XLID have been found. Nonetheless, intellectual disabilities that map to the X-chromosome remain unresolved in a large number of families, which suggests that more XLID genes or loci are yet to be identified.

To identify more XLID-linked genes investigators at the Max Planck Institute for Molecular Genetics (Berlin, Germany) employed massively parallel sequencing of all X-chromosome exons in the index males of 405 families with XLID of unknown origin. In total, 745 X-chromosomal genes were screened.

Results revealed that 80 families (20%) carried pathogenic variants in established XLID genes. In 19 families, the investigators detected likely causative protein truncating and missense variants in seven novel and validated XLID genes (CLCN4, CNKSR2, FRMPD4, KLHL15, LAS1L, RLIM, and USP27X) and potentially deleterious variants in two novel candidate XLID genes (CDK16 and TAF1). Furthermore, they showed that the CLCN4 and CNKSR2 variants impaired protein functions as indicated by electrophysiological studies and altered differentiation of cultured primary neurons from mice lacking CLCN4 or after mRNA knock-down.

"In addition to known disease-related genes, we have discovered seven novel genes as the cause of X-linked intellectual disability and analyzed what signaling pathways in the cells each protein is involved in," said senior author Dr. Vera Kalscheuer, professor of human molecular genetics at the Max Planck Institute for Molecular Genetics. "The clinical presentation and severity of the disorder depend on the responsible gene and the nature of the mutation."

The study was published in the February 3, 2015, online edition of the journal Molecular Psychiatry.

Related Links:

Max Planck Institute for Molecular Genetics



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.